208 related articles for article (PubMed ID: 33989702)
1. An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers.
Xu Y; Shrestha N; Préat V; Beloqui A
Adv Drug Deliv Rev; 2021 Aug; 175():113795. PubMed ID: 33989702
[TBL] [Abstract][Full Text] [Related]
2. Analyzing the metabolic fate of oral administration drugs: A review and state-of-the-art roadmap.
Liu L; Liu Y; Zhou X; Xu Z; Zhang Y; Ji L; Hong C; Li C
Front Pharmacol; 2022; 13():962718. PubMed ID: 36278150
[TBL] [Abstract][Full Text] [Related]
3. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
4. Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics.
Pade D; Jamei M; Turner DB; Mistry B; Martinez MN
Eur J Pharm Biopharm; 2019 Aug; 141():191-209. PubMed ID: 31150808
[TBL] [Abstract][Full Text] [Related]
5. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans.
Lennernäs H
Curr Drug Metab; 2007 Oct; 8(7):645-57. PubMed ID: 17979653
[TBL] [Abstract][Full Text] [Related]
6. A higher throughput and physiologically relevant two-compartmental human ex vivo intestinal tissue system for studying gastrointestinal processes.
Stevens LJ; van Lipzig MMH; Erpelinck SLA; Pronk A; van Gorp J; Wortelboer HM; van de Steeg E
Eur J Pharm Sci; 2019 Sep; 137():104989. PubMed ID: 31301485
[TBL] [Abstract][Full Text] [Related]
7. Intestinal uptake of insulin nanoparticles: facts or myths?
Lopes MA; Abrahim BA; Seiça R; Veiga F; Rodrigues CR; Ribeiro AJ
Curr Pharm Biotechnol; 2014; 15(7):629-38. PubMed ID: 25219866
[TBL] [Abstract][Full Text] [Related]
8. Intestinal Permeability and Oral Absorption of Selected Drugs Are Reduced in a Mouse Model of Familial Alzheimer's Disease.
Jin L; Pan Y; Tran NLL; Polychronopoulos LN; Warrier A; Brouwer KLR; Nicolazzo JA
Mol Pharm; 2020 May; 17(5):1527-1537. PubMed ID: 32212738
[TBL] [Abstract][Full Text] [Related]
9. Striving Towards the Perfect In Vitro Oral Drug Absorption Model.
Gleeson JP; McCartney F
Trends Pharmacol Sci; 2019 Oct; 40(10):720-724. PubMed ID: 31422894
[TBL] [Abstract][Full Text] [Related]
10. Correlation of in vitro and in vivo models for the oral absorption of peptide drugs.
Föger F; Kopf A; Loretz B; Albrecht K; Bernkop-Schnürch A
Amino Acids; 2008 Jun; 35(1):233-41. PubMed ID: 17726639
[TBL] [Abstract][Full Text] [Related]
11. Assessing the absorption of new pharmaceuticals.
Hidalgo IJ
Curr Top Med Chem; 2001 Nov; 1(5):385-401. PubMed ID: 11899104
[TBL] [Abstract][Full Text] [Related]
12. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
13. The potential of porcine ex vivo platform for intestinal permeability screening of FcRn-targeted drugs.
Azevedo C; Andersen JT; Traverso G; Sarmento B
Eur J Pharm Biopharm; 2021 May; 162():99-104. PubMed ID: 33771621
[TBL] [Abstract][Full Text] [Related]
14. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
15. Differentiated intestinal epithelial cell lines as in vitro models for predicting the intestinal absorption of drugs.
Wils P; Warnery A; Phung-Ba V; Scherman D
Cell Biol Toxicol; 1994 Dec; 10(5-6):393-7. PubMed ID: 7697502
[TBL] [Abstract][Full Text] [Related]
16. Targeting intestinal transporters for optimizing oral drug absorption.
Varma MV; Ambler CM; Ullah M; Rotter CJ; Sun H; Litchfield J; Fenner KS; El-Kattan AF
Curr Drug Metab; 2010 Nov; 11(9):730-42. PubMed ID: 21189135
[TBL] [Abstract][Full Text] [Related]
17. In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption.
del Amo EM; Heikkinen AT; Mönkkönen J
Eur J Pharm Sci; 2009 Feb; 36(2-3):200-11. PubMed ID: 19063964
[TBL] [Abstract][Full Text] [Related]
18.
Pinto S; Pintado ME; Sarmento B
Expert Opin Drug Deliv; 2020 Jan; 17(1):33-48. PubMed ID: 31786958
[No Abstract] [Full Text] [Related]
19. Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs.
Managuli RS; Raut SY; Reddy MS; Mutalik S
Expert Opin Drug Deliv; 2018 Aug; 15(8):787-804. PubMed ID: 30025212
[TBL] [Abstract][Full Text] [Related]
20. Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues.
Lundquist P; Artursson P
Adv Drug Deliv Rev; 2016 Nov; 106(Pt B):256-276. PubMed ID: 27496705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
